Form 6-K Avricore Health Inc. For: Sep 30

June 23, 2021 4:19 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of: September 2020

 

Commission File Number:  000-51848

 

 

Avricore Health Inc.

(Exact name of registrant as specified in its charter)

 

N/A

(Translation of Registrant’s name into English)

 

3500 – 1055 Dunsmuir Street PO Box 49114 Vancouver BC V7X1H7

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.      Form 20-F x Form 40-F o

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    Yes o No x

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Yes o No x

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form 6-K is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:    Yes o No x

 

 

Exhibits

 

The following exhibits are included in this Form 6-K:

 

Exhibit No.

Description

Date

99.1

News Release, Avricore Healths Health Tab TM to Enable Real Time Reporting of COVID-19 Results in Pharmacy

September 9, 2020

99.2

News Release, Avricore Health Amends Options

September 11, 2020

99.3

News Release, HealthTam TM Integrating New Device to Add HbA1c Blood Glucose Testing to Itss Real-Time Data Reporting System

September 22, 2020

 

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated:  June 23, 2021

AVRICORE HEALTH INC.

 

 

 

By: /s/ Kiki Smith

 

Kiki Smith

 

Chief Financial Officer


2

Exhibit 99.1

 

Picture 1 

 

Avricore Health’s HealthTabTM to Enable Real Time Reporting of COVID-19 Results in Pharmacy

VANCOUVER, British Columbia, September 9th, 2020 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore" or the "Company") a leader in pharmacy-based point-of-care testing solutions, plans to offer its HealthTabTM system as a stand-alone service to improve COVID-19 case reporting.

“Timely and accurate reporting is key to managing community outbreaks, but it can be a challenge for even the major laboratory networks as we’ve seen recently in the U.S.,” says Rodger Seccombe, Avricore Chief Technology Officer and Co-Founder of HealthTabTM. “Our middleware will bring plug-and-play, real-time electronic case reporting into community pharmacies. With new Health Canada licensed point-of-care devices expected later this year, we anticipate pharmacists will take on a greater role in COVID-19 testing and tracking.”

The Company offers a device agnostic point-of-care testing platform, including a web API, that allows data to flow with patient consent, directly from an analyzer to the health records and reporting systems being utilized in a particular region.

“As more point-of-care testing moves into pharmacies, HealthTabTM provides the opportunity to aggregate and report results in real-time to health authorities. It’s a highly scalable, flexible and affordable solution to improve key health data monitoring and reporting from within the community, not only for COVID-19 cases, but also for adverse drug reactions, liver toxicity, diabetes and chronic disease,” added Avricore CEO Hector Bremner.

About HealthTabÔ + RASTR

HealthTabÔ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTabÔ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.

Typically, HealthTabTM utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

As part of this direction for HealthTabÔ, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTabÔ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.


Picture 1 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

Contact:

Hector Bremner, CEO 604-773-8943

info@avricorehealth.com  
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTabTM platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Exhibit 99.2

Picture 1 

AVRICORE HEALTH AMENDS OPTIONS

VANCOUVER, BRITISH COLUMBIA – September 10, 2020) – AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”)  announces that its Board of Directors and Shareholders have approved (subject to TSXV approval) the re-pricing of a total of 2,091,072 options to purchase common shares ("Options") to an amended exercise price of $0.10 per Option (the "Re-Pricing").

The Re-Pricing of the Options was approved by the Board of Directors on February 2, 2020. The closing price of the Company's common shares on the TSXV on January 31, 2020, prior to the approval of the Re-Pricing, was $0.03.

150,000 of the Options had been issued on July 20, 2017 with an original exercise price of $0.15. 150,000 of the Options had been issued on September 27, 2017 at an original exercise price of $0.15. 150,000 of the Options had been issued on November 20, 2017 at an original exercise price of $0.28. 1,151,072 of the Options had been issued on December 8, 2017 at an original exercise price of $0.28. 200,000 of the Options had been issued on March 27, 2018 at an original exercise price of $0.24. 150,000 of the Options had been issued on April 11, 2018 at an original exercise price of $0.21 and 140,000 of the Options had been issued on September 12, 2018 at an original exercise price of $0.125.

The Re-Pricing of the Options was approved by the Shareholders at the Company's Annual General Meeting held on April 2, 2020. The Re-Pricing has been submitted for TSXV approval. Prior to the Company's receipt of TSXV approval, none of the Options may be exercised at the revised price.

Hector Bremner CEO stated, ”We feel the Re-Pricing will better align incentives to insiders, employees and consultants with the Company’s, immediate, short and long term objectives.”

Contact:

 

Hector Bremner, CEO 604-773-8943

info@avricorehealth.com 

www.avricorehealth.com 

 

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Exhibit 99.3

Picture 1 

 

HealthTab™ Integrating New Device to Add HbA1c Blood Glucose Testing to Its Real-Time Data Reporting System.

 

 

VANCOUVER, British Columbia, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore" or the "Company") is pleased to announce the signing of a Letter of Intent (LOI) with a prominent, publicly traded healthcare technology company and drug maker which serves as the foundation to integrate a propriety point-of-care blood chemistry analyzer into Avricore’s HealthTab™ real-time data reporting system. The companies will work together to license and market this new platform.

 

Under the terms of the LOI, Avricore will offer the HealthTab™ + RASTR system and technology for the collection, analysis and reporting of client data in the form of a web-based interface and mobile application both for consumers and sponsors.

 

“The ever-evolving point-of-care testing environment means integrating a variety of devices into HealthTab,” said Avricore Health CEO Hector Bremner. “By working with a world-leader with a strong commitment to the sector means a collaboration where our clients, many of which are mutual, can benefit from the best devices and our revolutionary data-flow technology.”

 

By interfacing the new analyzer with the HealthTab™ +RASTR, HealthTab™ will now be able to offer HbA1c blood glucose testing, expanding capabilities with respect to the detection of diabetes risk in patients, as well as supporting healthcare teams in managing treatment programs related to this disease.

 

 

About HealthTabÔ + RASTR

 

HealthTab is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.

 

Typically, HealthTab™ utilizes the Piccolo Express, an Abaxis Global Diagnostics device, however, the software is designed to be interfaceable with many devices and information management systems.


As part of this direction for HealthTab, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

 

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Contact:

 

Hector Bremner, CEO 604-773-8943

info@avricorehealth.com 

www.avricorehealth.com 

 

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings